An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany
← catalyst calendarNCT06169956 · readout in 1,503 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
400estimated
Sites
1
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-30 | actual | When the study began enrolling |
| Primary completion | 2030-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2023-12-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-04-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Resectable Non-small Cell Lung Cancer
Intervention
- Drug: Neoadjuvant nivolumab in combination with platinum-based chemotherapy
Primary outcome
what the primary-completion date above is the date OFEvent-free survival
measured Up to 5 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed